CA3127090A1 - Dual stem cell therapy for neurological conditions - Google Patents
Dual stem cell therapy for neurological conditions Download PDFInfo
- Publication number
- CA3127090A1 CA3127090A1 CA3127090A CA3127090A CA3127090A1 CA 3127090 A1 CA3127090 A1 CA 3127090A1 CA 3127090 A CA3127090 A CA 3127090A CA 3127090 A CA3127090 A CA 3127090A CA 3127090 A1 CA3127090 A1 CA 3127090A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- mscs
- hscs
- composition
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/815—Dopamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/081—Coculture with; Conditioned medium produced by cells of the nervous system neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1171—Haematopoietic stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/32—Polylysine, polyornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794041P | 2019-01-18 | 2019-01-18 | |
| US62/794,041 | 2019-01-18 | ||
| PCT/US2020/014041 WO2020150580A1 (en) | 2019-01-18 | 2020-01-17 | Dual stem cell therapy for neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3127090A1 true CA3127090A1 (en) | 2020-07-23 |
Family
ID=71614511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3127090A Pending CA3127090A1 (en) | 2019-01-18 | 2020-01-17 | Dual stem cell therapy for neurological conditions |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220072050A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3911342A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022517531A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127090A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020150580A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019071036A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | CONDUCTIVE POLYMER IMPLANT, COMBINING ELECTRICAL AND CHEMICAL STIMULATION TO IMPROVE NEURONAL RECOVERY |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050069597A1 (en) * | 1999-07-01 | 2005-03-31 | Thompson Ronald J. | Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of alprostadil for the treatment of female sexual dysfunction |
| JP4741189B2 (ja) * | 2002-02-08 | 2011-08-03 | ユニヴァーシティ オブ サウス フロリダ | 増殖した細胞系およびその使用方法 |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| WO2004090112A2 (en) * | 2003-04-01 | 2004-10-21 | United States Of America Department Of Veteran's Affairs | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| US8609082B2 (en) * | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
| WO2009011546A2 (en) * | 2007-07-16 | 2009-01-22 | Catholic University Industry Academic Cooperation Foundation | Method for promoting the self-renewal of adult stem cells using mesenchymal stromal cells |
| JP6998768B2 (ja) * | 2015-08-28 | 2022-02-10 | ロート製薬株式会社 | Ror1陽性の間葉系幹細胞及びその調製方法、ror1陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにror1陽性の間葉系幹細胞を用いる疾患の予防又は治療方法 |
| EP3231434A1 (en) * | 2016-04-14 | 2017-10-18 | Fundacio Centre de Regulacio Genomica | Method of treatment of parkinsonism |
-
2020
- 2020-01-17 US US17/417,289 patent/US20220072050A1/en not_active Abandoned
- 2020-01-17 EP EP20740959.0A patent/EP3911342A4/en not_active Withdrawn
- 2020-01-17 CA CA3127090A patent/CA3127090A1/en active Pending
- 2020-01-17 WO PCT/US2020/014041 patent/WO2020150580A1/en not_active Ceased
- 2020-01-17 JP JP2021537075A patent/JP2022517531A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072050A1 (en) | 2022-03-10 |
| WO2020150580A1 (en) | 2020-07-23 |
| EP3911342A1 (en) | 2021-11-24 |
| EP3911342A4 (en) | 2022-11-09 |
| JP2022517531A (ja) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9877989B2 (en) | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions | |
| Li et al. | Neural stem/progenitor cell‐derived extracellular vesicles: a novel therapy for neurological diseases and beyond | |
| AU2018243554B2 (en) | Generation of therapeutic cells using extracellular components of target organs | |
| Haghighitalab et al. | Investigating the effects of IDO1, PTGS2, and TGF-β1 overexpression on immunomodulatory properties of hTERT-MSCs and their extracellular vesicles | |
| WO2021195154A1 (en) | Isolation and purification of exosomes for regenerative medicine | |
| CA3012009A1 (en) | Methods for enhancing proliferation of t regulatory cells | |
| WO2021177473A1 (en) | Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation | |
| Kurtzberg et al. | Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases | |
| US20240197776A1 (en) | Cancer-killing cells | |
| Zhu et al. | Efficacy of surgery combined with autologous bone marrow stromal cell transplantation for treatment of intracerebral hemorrhage | |
| Lee et al. | Role of IGF1R+ MSCs in modulating neuroplasticity via CXCR4 cross-interaction | |
| EP4123019A1 (en) | Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof | |
| EP4082613A1 (en) | Cell group and method for acquiring same | |
| US20220072050A1 (en) | Dual Stem Cell Therapy for Neurological Conditions | |
| Blázquez-Prunera et al. | Human bone marrow mesenchymal stem/stromal cells preserve their immunomodulatory and chemotactic properties when expanded in a human plasma derived xeno‐free medium | |
| Sabry et al. | Comparative evaluation for potential differentiation of endothelial progenitor cells and mesenchymal stem cells into endothelial-like cells | |
| Xie | Evaluating the Mechanisms of Action of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Ischemic Stroke | |
| CN104995295A (zh) | 多分化潜能细胞的制造方法 | |
| Anbeek | Investigating human milk extracellular vesicles as therapeutic agents: a study on their efficacy in in vitro hit models of premature encephalopathy | |
| Bhaskara | Characterization and therapeutic potential of placenta-derived mesenchymal stem/stromal cells isolated in serum-free culture media | |
| EP4483887A1 (en) | Cell preparation | |
| Kurtzberg et al. | Reprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases | |
| EP4227406A1 (en) | Method for stimulation of mesenchymal cells to induce immunomodulatory factor expression | |
| Donders | Umbilical cord stem cells as a candidate therapy for multiple sclerosis | |
| WO2019241820A1 (en) | Method of generating multi-lineage potential cells and multi-lineage potential cells produced therefrom |